Blab Business
Natera Reports Strong Q2 2026 Growth, Raises 2026 Revenue Outlook Amid Valuation Headwinds
Natera, Inc. (NASDAQ: NTRA) unveiled its second‑quarter 2026 earnings on August 6, 2026, revealing a surge in revenue and test volumes that prompted the company to lift its annual revenue guidance.
Total revenue climbed to $752.8 million, a 37.7 % jump from $546.6 million a year earlier. The company processed roughly 1.04 million tests, up 57.2 % year‑over‑year, and posted a gross margin of 64.5 %. Net loss for the quarter was $67 million, or $0.47 per diluted share, compared with a $0.74 loss a year before.
The results underscore the rapid expansion of Natera’s Signatera minimal residual disease (MRD) platform. Clinical MRD volume rose to about 283,000 units, an increase of 56 % from the prior year. On the same day the earnings were released, Natera also secured regulatory approval for Signatera in Japan for colorectal cancer, extending the platform beyond the U.S. market.
At the earnings call, management raised its 2026 revenue outlook by $100 million, now projecting total revenue of $2.85 billion to $2.91 billion. The company reiterated its expectation of positive cash flow for the year and forecast research and development expenses of $800 million to $900 million.
Chief Executive Officer Steve Chapman cautioned that the company does not anticipate setting a new test‑volume record in the third quarter. He noted that the sequential increase in clinical MRD volume during the second quarter was 34,000 units, the largest jump to date, but that growth is likely to slow.
Natera is also broadening its transplant portfolio. Medicare surveillance coverage for Prospera, the company’s organ‑transplant monitoring platform, took effect on August 30 for kidney, heart and lung recipients. The expanded coverage is expected to drive additional test volumes in the coming quarters.
Despite the revenue gains, the company remains unprofitable. The net loss narrowed from $100.9 million a year earlier to $67 million, but the operating loss widened from $75.8 million to $110.4 million year‑ago. Gross margin has improved, yet the cost structure—driven largely by R&D and selling, general and administrative expenses—continues to weigh on profitability.
Natera’s share price has surged 93 % year‑to‑date, trading around $328 on September 4. On the same day, CNBC’s Jim Cramer, who described the company as a “precision medicine platform” on his show Mad Money, cautioned that the stock’s valuation is difficult to justify after the recent rally. He noted that the shares trade at roughly 16 times the company’s expected sales for the year, not earnings, and that the company is still losing money.
Cramer also highlighted competitive pressures. He said that rivals are investing heavily in liquid biopsy and cancer monitoring, and that reimbursement and regulatory standards remain uncertain. He added that Wall Street generally expects Natera to become profitable in 2028, with significant earnings growth through 2031.
The company’s risks include competition, reimbursement, regulatory requirements, clinical validation and adoption of its tests. Natera’s management has acknowledged these factors in its guidance and investor presentations.
Looking ahead, investors will watch the company’s third‑quarter results for test‑volume trends, the impact of Medicare coverage for Prospera, and any updates on Signatera’s international expansion. The company’s next earnings call will also provide further detail on the 2026 revenue outlook, gross‑margin expectations and cash‑flow projections.
In summary, Natera’s Q2 2026 results demonstrate strong revenue growth and expanding test volumes, particularly in oncology through its Signatera platform. The company has raised its annual revenue forecast and maintains a positive cash‑flow outlook for 2026, but remains unprofitable and faces competitive and regulatory headwinds that may influence its valuation and future profitability.
Total revenue climbed to $752.8 million, a 37.7 % jump from $546.6 million a year earlier. The company processed roughly 1.04 million tests, up 57.2 % year‑over‑year, and posted a gross margin of 64.5 %. Net loss for the quarter was $67 million, or $0.47 per diluted share, compared with a $0.74 loss a year before.
The results underscore the rapid expansion of Natera’s Signatera minimal residual disease (MRD) platform. Clinical MRD volume rose to about 283,000 units, an increase of 56 % from the prior year. On the same day the earnings were released, Natera also secured regulatory approval for Signatera in Japan for colorectal cancer, extending the platform beyond the U.S. market.
At the earnings call, management raised its 2026 revenue outlook by $100 million, now projecting total revenue of $2.85 billion to $2.91 billion. The company reiterated its expectation of positive cash flow for the year and forecast research and development expenses of $800 million to $900 million.
Chief Executive Officer Steve Chapman cautioned that the company does not anticipate setting a new test‑volume record in the third quarter. He noted that the sequential increase in clinical MRD volume during the second quarter was 34,000 units, the largest jump to date, but that growth is likely to slow.
Natera is also broadening its transplant portfolio. Medicare surveillance coverage for Prospera, the company’s organ‑transplant monitoring platform, took effect on August 30 for kidney, heart and lung recipients. The expanded coverage is expected to drive additional test volumes in the coming quarters.
Despite the revenue gains, the company remains unprofitable. The net loss narrowed from $100.9 million a year earlier to $67 million, but the operating loss widened from $75.8 million to $110.4 million year‑ago. Gross margin has improved, yet the cost structure—driven largely by R&D and selling, general and administrative expenses—continues to weigh on profitability.
Natera’s share price has surged 93 % year‑to‑date, trading around $328 on September 4. On the same day, CNBC’s Jim Cramer, who described the company as a “precision medicine platform” on his show Mad Money, cautioned that the stock’s valuation is difficult to justify after the recent rally. He noted that the shares trade at roughly 16 times the company’s expected sales for the year, not earnings, and that the company is still losing money.
Cramer also highlighted competitive pressures. He said that rivals are investing heavily in liquid biopsy and cancer monitoring, and that reimbursement and regulatory standards remain uncertain. He added that Wall Street generally expects Natera to become profitable in 2028, with significant earnings growth through 2031.
The company’s risks include competition, reimbursement, regulatory requirements, clinical validation and adoption of its tests. Natera’s management has acknowledged these factors in its guidance and investor presentations.
Looking ahead, investors will watch the company’s third‑quarter results for test‑volume trends, the impact of Medicare coverage for Prospera, and any updates on Signatera’s international expansion. The company’s next earnings call will also provide further detail on the 2026 revenue outlook, gross‑margin expectations and cash‑flow projections.
In summary, Natera’s Q2 2026 results demonstrate strong revenue growth and expanding test volumes, particularly in oncology through its Signatera platform. The company has raised its annual revenue forecast and maintains a positive cash‑flow outlook for 2026, but remains unprofitable and faces competitive and regulatory headwinds that may influence its valuation and future profitability.
